Corcept Therapeutics Incorporated - Common Stock — 분기별 재무 통계 (NASDAQ:CORT)

Financials

영업활동으로 인한 현금 59.83 M5.13 M44.3 M54.48 M38.45 M-16.77 M 120.45 M 투자 활동으로 인한 현금 -64.36 M-3.17 M70.13 M14.64 M-11.84 M4.54 M 77.47 M 재무활동으로 인한 현금 -4.56 M-39.8 M-102.93 M-46.41 M-31.22 M760 K -179.8 M 잉여 현금 흐름 59.83 M5.13 M44.3 M54.48 M38.45 M-16.77 M 120.45 M

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated - Common Stock

뉴스

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

Chip Stock Strength Lifts the Broader Market

Stocks Pressured by Signs of Resurgent Inflation

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement (NASDAQ:CORT)

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ:CORT)

Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?